The relationship of hyperuricemia to kidney disease, diabetes, hypertension and the risk of cardiovascular diseases remain controversial. The aim of this study is to evaluate the use of uric acid (UA) levels to find the higher risk of cardiovascular disease (CVD) in patients with end stage renal disease that have diabetic nephropathy (DN), nephropathy with hypertension (NH) and patients with both diabetic nephropathy with hypertension (DNH). This study deals with 115 patients with end-stage renal disease under hemodialysis sub-grouped into 35 patients with (DN), 40 patients with (NH), and 40 patients with (DNH). Some biochemical parameters were determined in the serum of all participants such as HbA1c, fasting blood glucose (FBG), UA, urea, serum creatinine, total serum protein, calcium, phosphate, albumin, and globin levels. The present study revealed a significant increase (P<0.05) in HbA1c, FBG, urea and creatinine in DN and DNH patients compared to NH group. However, non-significant difference was found in total serum protein, serum albumin, globulin, calcium, and phosphate levels between the groups. A positive correlation was found between UA level with FBG, HbA1c and creatinine in DN and DNH groups in comparison to NH group. Levels of UA can be considered as a reliable marker, which is less expensive and helps clinicians in controlling the progression to microvascular complications. The early detection of any complication and adopting the appropriate treatment to reduce the risk of CVD can reduce morbidity and mortality.
